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A B S T R A C T
Purpose
To update a clinical practice guideline (CPG) for the empirical management of fever and neutropenia
(FN) in children with cancer and hematopoietic stem-cell transplantation recipients.
Methods
The International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and mul-
tinational group of experts in pediatric oncology and infectious diseases that includes a patient
advocate. For questions of risk stratification and evaluation, we updated systematic reviews of
observational studies. For questions of therapy, we conducted a systematic review of randomized
trials of any intervention applied for the empirical management of pediatric FN. The Grading of
Recommendation Assessment, Development and Evaluation approach was used to make strong or
weak recommendations and to classify levels of evidence as high, moderate, low, or very low.
Results
Recommendations related to initial presentation, ongoing management, and empirical antifungal
therapy of pediatric FN were reviewed; the most substantial changes were related to empirical
antifungal therapy. Key differences from our 2012 FN CPG included the listing of a fourth-generation
cephalosporin for empirical therapy in high-risk FN, refinement of risk stratification to define patients
with high-risk invasive fungal disease (IFD), changes in recommended biomarkers and radiologic
investigations for the evaluation of IFD in prolonged FN, and a weak recommendation to withhold
empirical antifungal therapy in IFD low-risk patients with prolonged FN.
Conclusion
Changes to the updated FN CPG recommendations will likely influence the care of pediatric patients
with cancer and those undergoing hematopoietic stem-cell transplantation. Future work should
focus on closing research gaps and on identifying ways to facilitate implementation and
adaptation.
J Clin Oncol 35:2082-2094. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Fever and neutropenia (FN) is a common com-
plication of cancer treatment. In 2012, we pub-
lished a clinical practice guideline (CPG) focused
on the management of FN in children with cancer
and in recipients of hematopoietic stem-cell
transplantation (HSCT).1 Like all CPGs, it is
important that the systematic reviews that in-
form the recommendations are timely, typically
considered every 5 years in the absence of im-
portant new studies. Consequently, we updated
the systematic reviews and present the 2017 pe-
diatric FN CPG.
METHODS
The International Pediatric Fever and Neutropenia
Guideline Panel includes representation from pediatric
oncology, infectious diseases, nursing, and pharmacy, as
well as a patient advocate and a guideline methodologist
from 10 different countries (Data Supplement).
The methodology applied to our CPG update
mirrored our 2012 FN CPG. We followed previously
validated procedures for creating evidence-based
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guidelines2 and used the Appraisal of Guidelines for Research & Evaluation II
instrument as a framework.3 Eachmember completed a conflict of interest form
(Data Supplement). The funding agencies had no role to play in the recom-
mendations or editing of the manuscript. The Grading of Recommendation
Assessment, Development and Evaluation approach was used to generate rec-
ommendations. Details of methodology may be found in the Data Supplement.
Members were divided into working groups that focused on the three
major sections addressed in the initial CPG: initial presentation, ongoing
management, and empirical antifungal therapy. Given the paucity of pe-
diatric data at the time of initial CPG development, none of the original
systematic reviews were restricted to randomized controlled trials (RCTs).
For the guideline update, we decided to focus on pediatric RCTs for questions
related to therapy because we believed that clinical practice was unlikely to
change on the basis of additional observational studies alone. For questions
related to risk stratification and evaluation, the original systematic reviews
were updated. The Data Supplement contains details of the search strategies,
flow diagrams of study identification and selection, and eligibility criteria.
RECOMMENDATIONS AND EXPLANATIONS
Table 1 presents the 2017 recommendations, highlights changes
from the 2012 FN CPG, and provides key remarks. The associated
evidence profiles are illustrated in the Data Supplement when data
were not published in separate manuscripts. Research gaps are
presented in Table 2.
SECTION A: INITIAL PRESENTATION OF FN
Question
What clinical features and laboratory markers can be used to
classify pediatric patients with FN as being at low risk or high risk
of poor outcomes?
Recommendation
A1. Adopt a validated risk stratification strategy (Table 3) and
incorporate it into routine clinical management (strong
recommendation, low-quality evidence).
Literature update and analysis. The 2012 recommendation was
derived from a systematic review16 that demonstrated a number of
schemas that varied by patients included, definitions of FN, and
outcomes measured. Updating the systematic review (Data Supple-
ment) demonstrated further validation of previously published
schemas, andmore small studies deriving new rules. Six clinically based
low-risk stratification schemas that rely on a single assessment at
presentation have been validated in different pediatric populations
(Table 3). Even with further information, we remain unable to clearly
recommend any single prediction rule. There remains evidence of
geographical and temporal variation; thus, all schemas require local
validation before use. The choice of strategy should be determined by
an institution’s ability to implement more complex rules and the
timeliness of receipt of required components of the rule, such as
C-reactive protein. Two additional risk stratification schemas including
repeated measurement of biomarkers have been derived and suc-
cessfully validated in their originating groups.17,18 These use clinical
assessment and IL-8 measurements for all pediatric patients17 or IL8
and C-reactive protein for a high-risk group.18
Question
What clinical, laboratory, and imaging studies are useful at the
initial presentation of FN to assess the cause of the episode and
guide future treatment?
Recommendations
A2. Obtain blood cultures at the onset of FN from all lumens of
central venous catheters (strong recommendation, low-
quality evidence).
A3. Consider obtaining peripheral blood cultures concurrent
with central venous catheter cultures (weak recommen-
dation, moderate-quality evidence).
A4. Consider urinalysis and urine culture in patients in whom
a clean-catch, midstream specimen is readily available (weak
recommendation, low-quality evidence).
A5. Obtain chest radiography (CXR) only in patients with re-
spiratory signs or symptoms (strong recommendation,
moderate-quality evidence).
Literature update and analysis. The value of peripheral blood
cultures has been addressed in nine studies,19-27 two of which were
published after 2011.19,20 The updated estimate of the proportion of
true bacteremia episodes detected by peripheral blood cultures alone,
when central venous catheter cultures are negative, was 12% (95%CI,
8%–17%). Thus, peripheral cultures consistently increase the
identification of true bacteremia compared with central cultures
alone, which may be related to timing or volume. It is a weak
recommendation because the impact of increased yield is unknown
and it should be balanced against pain and isolation of contaminants.
In terms of urinalysis and urine culture to detect urinary tract
infections in pediatric FN, in one study, all patients with positive urine
cultures were asymptomatic,28 strengthening the conclusion that
restricting urine culture to those with symptoms is not adequate. The
use of abnormal urinalysis to triage culture is also not recommended
because pyuria was present in only 4% of urinary tract infection
episodes during neutropenia29 and nitrite testing in younger children
(without cancer) is less discriminatory than in older patients.30
Two additional studies have been added to the initial sys-
tematic review16 of the use of routine CXR during the initial as-
sessment of pediatric FN. One was undertaken in a broad cohort of
patients with FN31 and one in children undergoing HSCT.32 Both
demonstrated rates of pneumonia of , 3% in an asymptomatic
child. Asymptomatic children who did not undergo CXR had no
significant adverse clinical consequences.33 Thus, no change was
made to the strong recommendation to obtain CXR only in pa-
tients with respiratory signs or symptoms.
Question
What empirical antibiotics are appropriate for children with
high-risk FN?
Recommendations
A6. In high-risk FN:
A6a. Use monotherapy with an antipseudomonal b-lactam,
a fourth-generation cephalosporin, or a carbapenem as
empirical therapy in pediatric high-risk FN (strong rec-
ommendation, high-quality evidence).
A6b. Reserve the addition of a second gram-negative agent or
a glycopeptide for patients who are clinically unstable, when
a resistant infection is suspected, or for centers with a high
rate of resistant pathogens (strong recommendation,
moderate-quality evidence).
Literature update and analysis. In the systematic review of
RCTs of pediatric FN, we compared monotherapy with
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aminoglycoside-containing combination therapy, and the re-
sults are presented in Table 4.34 In this comparison, a rate
ratio . 1 indicates that monotherapy is better than combi-
nation therapy. No significant differences in failure rates,
infection-related mortality, or overall mortality were observed.
Three studies were conducted solely in patients with high-risk
FN,35-37 and among these studies, no difference in treat-
ment failure was observed (rate ratio, 1.14; 95% CI, 0.54 to 2.39;
P = .73). However, it is important to note that these three RCTs did
not evaluate monotherapy with a b-lactam against the same
b-lactam plus an aminoglycoside, thus highlighting the impor-
tance of the specific monotherapy b-lactam antibiotic used.
This analysis confirmed the efficacy and safety of monotherapy
without the addition of aminoglycosides in treatment settings
in which resistance rates were low enough to permit random
assignment between monotherapy and combination therapy.
Consequently, the updated CPG continues to have a strong rec-
ommendation to use empirical monotherapy in high-risk FN.
Table 1. Overall Summary of Recommendations, Changes, and Remarks
Recommendation Change From Previous Guideline Remarks
Initial management
Risk stratification
A1. Adopt a validated risk stratification strategy
and incorporate it into routine clinical
management (strong recommendation,
low-quality evidence).
None Strategy choice should be determined by
validation in a similar context, and ability to
implement based on complexity and
availability of required components such as
biomarkers.
Evaluation
A2. Obtain blood cultures at the onset of FN
from all lumens of central venous
catheters (strong recommendation,
low-quality evidence).
None
A3. Consider obtaining peripheral blood
cultures concurrent with central venous
catheter cultures (weak recommendation,
moderate-quality evidence).
Quality of evidence increased to
moderate from low
Peripheral cultures consistently increase
identification of true bacteremia compared
with central cultures alone. It is a weak
recommendation because the impact of
increased yield is unknown and should be
balanced against pain and isolation of
contaminants.
A4. Consider urinalysis and urine culture in
patients in whom a clean-catch,
midstream specimen is readily available
(weak recommendation, low-quality
evidence).
None Antibiotics should not be delayed to obtain
urine specimen.
A5. Obtain chest radiography only in patients
with respiratory signs or symptoms
(strong recommendation, moderate-
quality evidence).
None
Treatment
A6. In high-risk FN:
A6a. Use monotherapy with an
antipseudomonal b-lactam, a fourth-
generation cephalosporin, or
a carbapenem as empirical therapy in
pediatric high-risk FN (strong
recommendation, high-quality evidence).
Fourth-generation cephalosporin
added
The Panel valued the consistency of data
suggesting efficacy and safety of
monotherapy in pediatric randomized trials.
Monotherapy may not be appropriate for
centers with a high rate of resistance, or for
patients who present with hemodynamic
instability.
A6b. Reserve addition of a second gram-
negative agent or a glycopeptide for
patients who are clinically unstable,
when a resistant infection is suspected,
or for centers with a high rate of resistant
pathogens (strong recommendation,
moderate-quality evidence).
None Threshold for when rates of resistance are
sufficiently high to support empirical
combination or glycopeptide therapy has not
been established and will vary by institution
depending on preferences and available
alternatives.
A7. In low-risk FN:
A7a. Consider initial or step-down outpatient
management if the infrastructure is in
place to ensure careful monitoring and
follow-up (weak recommendation,
moderate-quality evidence).
None It is a weak recommendation because
institutions must have the infrastructure in
place to safely implement outpatient
management. Clinical outcomes were
similar between strategies and thus,
resources and preferences are important
considerations.
A7b. Consider oral antibiotic administration if
the child is able to tolerate this route of
administration reliably (weak
recommendation, moderate-quality
evidence).
None It is a weak recommendation because
readmission may be higher among
outpatients treated with oral v parenteral
therapy, and other outcomes were similar.
Thus, resources and preferences are
important considerations.
(continued on following page)
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Table 1. Overall Summary of Recommendations, Changes, and Remarks (continued)
Recommendation Change From Previous Guideline Remarks
Ongoing management
Modification of treatment
B1. In patients who are responding to initial
empirical antibiotic therapy, discontinue
double coverage for gram-negative
infection or empirical glycopeptide (if
initiated) after 24 to 72 hours if there is no
specific microbiologic indication to
continue combination therapy (strong
recommendation, moderate-quality
evidence).
None Rationale is same as that for the
recommendation for initial empirical
monotherapy. The Panel valued reducing
unnecessary antibiotic administration to
reduce toxicity, costs, and antibiotic
resistance.
B2. Do not modify the initial empirical
antibacterial regimen based solely on
persistent fever in children who are
clinically stable (strong recommendation,
low-quality evidence).
None
B3. In children with persistent fever who
become clinically unstable, escalate the
initial empirical antibacterial regimen to
include coverage for resistant gram-
negative, gram-positive, and anaerobic
bacteria (strong recommendation, very
low-quality evidence).
None
Cessation of treatment
B4. In all patients, discontinue empirical
antibiotics in patients who have negative
blood cultures at 48 hours, who have been
afebrile for at least 24 hours, andwho have
evidence of marrow recovery (strong
recommendation, low-quality evidence).
None A specific threshold to define count recovery
has not been established.
B5. In patients with low-risk FN, consider
discontinuation of empirical antibiotics at
72 hours in patients who have negative
blood cultures and who have been afebrile
for at least 24 hours, irrespective of
marrow recovery status, as long as careful
follow-up is ensured (weak
recommendation, moderate-quality
evidence).
None Although safety of early discontinuation of
empirical antibiotics in low-risk FN has been
examined, the specific question of early
discontinuation in the setting of no bone
marrow recovery has not been directly
addressed, thus leading to the weak
recommendation.
Empirical antifungal therapy
Risk stratification
C1. Patients at high risk of IFD are those with
AML, high-risk ALL, or relapsed acute
leukemia, and children undergoing
allogeneic HSCT. Children with prolonged
neutropenia and children receiving high-
dose corticosteroids are also at high risk of
IFD. All others should be categorized as
IFD low risk (strong recommendation,
low-quality evidence).
Risk factors refined. Quality of evidence
decreased to low from moderate
Risk stratification rules are not yet available for
prediction of IFD. The Panel recognized that
high-risk ALL is a heterogeneous group and
this risk may be explained by prolonged
neutropenia and corticosteroid
administration. However, data to provide
further specification around which patient
with ALL is at particular risk of IFD and
treatment periods of IFD risk are not
available.
Evaluation
C2. In terms of biomarkers to guide empirical
antifungal management for prolonged
($ 96 hours) FN in IFD high-risk patients:
C2a. Consider not using serum GM (weak
recommendation, moderate-quality
evidence).
Previously had been weak recommendation for
GM for surveillance and during FN. Now weak
recommendation against GM and restricted
recommendation to prolonged FN
The Panel deliberated over how GM results
would be used clinically and the impact of
poor positive predictive values in the setting
of typical IFD rates. Poor positive predictive
values mean that actions based on test
results are often incorrect. High negative
predictive values are less useful because
GM does not rule out non-Aspergillusmolds.
C2b. Do not use b-D-glucan. Strong
recommendation, low-quality evidence
None Poor positive predictive values and limited data
in prolonged FN setting
C2c. Do not use fungal PCR testing in blood
(strong recommendation, moderate-
quality evidence).
New recommendation Poor positive predictive values. Negative
predictive values not sufficiently high to be
clinically useful. PCR testing not yet
standardized.
(continued on following page)
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However, local epidemiology and resistance patterns should be
evaluated regularly.
Table 4 also demonstrates the comparison between anti-
pseudomonal penicillin monotherapy and fourth-generation ceph-
alosporin monotherapy.38-42 Five studies were included; one study42
was identified in the updated search after publication of the FN
systematic review.34 No differences in treatment failure, infection-
related mortality, or duration of fever were observed, and the point
estimate for mortality was in favor of the fourth-generation ceph-
alosporin, thus arguing for its inclusion in the empirical antibiotic
recommendation. The 0.81 day increase in duration of antibiotics
associated with cephalosporin therapy was not considered clinically
meaningful.
Question
In children with low-risk FN, is initial or step-down out-
patient management as effective and safe as inpatient management?
Is initial or step-down oral antibiotic management as effective and
safe as management with parenteral antibiotics?
Recommendations
A7. In low-risk FN:
A7a. Consider initial or step-down outpatient management if
the infrastructure is in place to ensure careful monitoring
and follow-up (weak recommendation, moderate-quality
evidence).
A7b. Consider oral antibiotic administration if the child is able to
tolerate this route of administration reliably (weak rec-
ommendation, moderate-quality evidence).
Literature update and analysis. In the systematic review of
pediatric FN RCTs, treatment setting and route of antibiotic ad-
ministration were examined34 (Table 4). Four studies randomized
patients to inpatient versus outpatient therapy43-46; no differences
in outcomes were observed. The point estimates favored outpatient
management in the mortality analyses, and no infection-related
deaths were reported for the 124 randomly assigned low-risk
patients treated as outpatients. It is a weak recommendation be-
cause institutions must have the infrastructure in place to safely
implement outpatient management. Because clinical outcomes
were similar among strategies, resources and preferences are im-
portant considerations in strategy choice.
Table 4 also lists the comparison between intravenous and oral
therapy among patients treated in the same setting (n = eight
studies).47-54 There was no significant difference in treatment failure,
and no infection-related mortality was reported among the 470
patients randomly assigned to receive oral empirical therapy. It is
a weak recommendation because readmission may be higher among
outpatients treated with oral versus parenteral therapy, and other
outcomes were similar. Thus, resources and preferences are important
considerations.
SECTION B: ONGOING MANAGEMENT OF FN
EXCLUDING EMPIRICAL THERAPY
Question
When and how should the initial empirical antibiotic therapy
be modified during the pediatric FN episode?
Table 1. Overall Summary of Recommendations, Changes, and Remarks (continued)
Recommendation Change From Previous Guideline Remarks
C3. In terms of imaging for the evaluation of
prolonged ($ 96 hours) FN in IFD high-risk
patients:
C3a. Perform CT of the lungs (strong
recommendation, low-quality evidence).
Quality of evidence decreased to low from
moderate
Lungs consistently the most commonly
affected site. Optimal timing of initial and
repeated imaging not known.
C3b. Consider imaging of abdomen in patients
without localizing signs or symptoms
(weak recommendation, low-quality
evidence).
New recommendation Ideal imaging modality not known, but
ultrasound is readily available, is not
associated with radiation exposure, usually
does not require sedation, and thus is likely
preferable over CT or MRI.
C3c. Consider not routinely performing CT of
sinuses in patients without localizing
signs or symptoms (weak
recommendation, low-quality evidence).
Previously had been weak recommendation for
CT sinuses. Now weak recommendation
against CT sinuses
Sinus imaging is frequently abnormal in
prolonged FN, and abnormalities do not
seem to distinguish between those with and
without sinus IFD. It is a weak
recommendation because studies directly
addressing the usefulness of routine sinus
CTs are limited.
Treatment
C4. In IFD high-risk patients with prolonged
($ 96 hours) FN unresponsive to broad-
spectrum antibacterial agents, initiate
caspofungin or liposomal amphotericin
B for empirical antifungal therapy (strong
recommendation, high-quality evidence).
None
C5. In IFD low-risk patients with prolonged
($ 96 hours) FN, consider withholding
empirical antifungal therapy (weak
recommendation, low-quality evidence).
Previously had been weak recommendation for
empirical therapy for IFD low-risk patients.
Now weak recommendation against empirical
therapy for IFD low-risk patients
Single randomized trial showed similar
outcomes with providing v withholding
empirical antifungal therapy for IFD low-risk
patients. However, the study was small and
thus considerable imprecision exists,
resulting in a weak recommendation.
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CT, computed tomography; FN, fever and neutropenia; GM, galactomannan; MRI,
magnetic resonance imaging; PCR, polymerase chain reaction.
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Recommendations
B1. In patients who are responding to initial empirical antibiotic
therapy, discontinue double coverage for gram-negative
infection or empirical glycopeptide (if initiated) after 24
to 72 hours if there is no specific microbiologic indication to
continue combination therapy (strong recommendation,
moderate-quality evidence).
B2. Do not modify the initial empirical antibacterial regimen
based solely on persistent fever in children who are clinically
stable (strong recommendation, low-quality evidence).
B3. In children with persistent fever who become clinically
unstable, escalate the initial empirical antibacterial regimen
to include coverage for resistant gram-negative, gram-
positive, and anaerobic bacteria (strong recommendation,
very low-quality evidence).
Literature update and analysis. In the 2012 FN CPG, early
discontinuation of combination therapy was based on the rationale
for initial monotherapy without the addition of an aminoglycoside or
empirical glycopeptide. As described previously, the recent systematic
review confirmed the efficacy and safety of monotherapy without the
addition of an aminoglycoside.34 The evidence remains indirect because
the RCTs were in the setting of initial therapy and not ongoing therapy
and consequently, this reduces the evidence quality to moderate.
There were no pediatric RCTs that evaluated the role of continuing
empirical glycopeptides or the appropriate course of action in patients
with persistent fever who remain clinically stable or who deteriorate.
Thus, there were no changes to the 2012 recommendations.
Question
When can empirical antibiotics be discontinued in patients
with low- and high-risk FN?
Recommendations
B4. In all patients, discontinue empirical antibiotics in patients
who have negative blood cultures at 48 hours, who have
been afebrile for at least 24 hours, and who have evidence
of marrow recovery (strong recommendation, low-quality
evidence).
B5. In patients with low-risk FN, consider discontinuation of
empirical antibiotics at 72 hours in patients who have neg-
ative blood cultures and who have been afebrile for at least
24 hours, irrespective of marrow recovery status, as long as
careful follow-up is ensured (weak recommendation,
moderate-quality evidence).
Literature update and analysis. The 2012 CPG recommen-
dation to discontinue antibiotics in patients with negative blood
cultures who have been afebrile for at least 24 hours and who have
evidence of count recovery was based on a summary of both
randomized and observational trials.55-74 In that analysis, the risk
of recurrent fever was low in patients with definitive marrow
recovery.
No new RCTs of antibiotic cessation were identified in our
recent systematic review,34 and thus, the recommendations have
not changed. Two RCTs included in the 2012 CPG compared early
cessation with continuation of empirical antibiotics.58,75 Both
studies were small and showed no differences in outcomes. However,
it is notable that the two patients with bacteremia (viridans group
streptococci and Enterobacter aerogenes) were both in the cessation
arm. Importantly, a large proportion of patients in one study75 had
evidence of marrow recovery at the time of random assignment,
whereas this proportionwas not stated in the second study.58 Thus, it
remains a weak recommendation to discontinue antibiotics in low-
risk patients who have been afebrile for at least 24 hours but who
have no evidence of count recovery on Day 3, because the specific
question of safety of antibiotic discontinuation without marrow
recovery has not been directly addressed.
The optimal duration of empirical antibiotics for high-risk pa-
tients with sustained bone marrow suppression was not addressed in
the systematic review34 and continues to be an important research gap.
SECTION C: EMPIRICAL ANTIFUNGAL TREATMENT
Question
What clinical parameters can classify pediatric patients with
persistent FN as high risk or low risk of invasive fungal disease
(IFD)?
Recommendation
C1. Patients at high risk of IFD are those with acute myeloid
leukemia, high-risk acute lymphoblastic leukemia (ALL), or
relapsed acute leukemia, and children undergoing allogeneic
HSCT. Children with prolonged neutropenia and children
receiving high-dose corticosteroids are also at high risk of
IFD. All others should be categorized as IFD low risk (strong
recommendation, low quality evidence).
Literature update and analysis. The updated CPG was mod-
ified based on a systematic review of risk factors for IFD specifically
in pediatric oncology and HSCTrecipients.75a This review included
22 studies76-97 and confirmed most risk factors for IFD previously
described in the 2012 CPG. However, additional factors now
Table 2. Research Gaps
Initial presentation
Optimal temperature threshold to define fever
New serum biomarkers as diagnostic and monitoring aids
Impact of viral diagnosis and the role of systemic viruses on
management of FN
Appropriate monitoring and follow-up for outpatient therapy
Optimal choice of empirical antibiotics in low-risk FN
Ongoing management
Timing and necessity of repeated blood cultures for persistent fever
Duration of empirical antibiotics for low- and high-risk FN
Role of providing targeted antibiotics only v continuing broad-spectrum
coverage in patients with positive cultures who remain neutropenic
Determining whether the diagnostic and therapeutic approach should differ
between patients with prolonged continuous fever v recurrent fever
during FN
Empirical antifungal management
Role of combination biomarkers for IFD evaluation and ongoing
management
Identifying novel biomarkers for IFD detection
Role and timing of standard imaging on patient outcomes
Efficacy and safety of pre-emptive antifungal therapy*
Appropriate duration of empirical antifungal therapy
Determining appropriate pediatric dosing for currently available antifungal
agents, and identifying novel antifungal agents for empirical therapy
Overall
Cost effectiveness of different approaches to manage pediatric FN
Abbreviations: FN, fever and neutropenia; IFD, invasive fungal disease.
*Defined as initiating systemic antifungal therapy initiation only on clinical,
radiologic, or biomarker evidence of IFD.
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specified include high-risk ALL and high-dose corticosteroids.
The Panel recognized that high-risk ALL is a heterogeneous
group and that the risk of IFD may be explained by prolonged
neutropenia and corticosteroid administration. However, data to
provide further specification around which patient with ALL is at
particular risk of IFD and the treatment phases of elevated risk are
not available.
Question
What clinical features, laboratory tests, and imaging studies
are useful to identify a fungal cause for persistent or recurrent FN
despite broad-spectrum antibiotics?
Recommendations
C2. In terms of biomarkers to guide empirical antifungal
management for prolonged ($ 96 hours) FN in IFD high-
risk patients:
C2a. Consider not using serum galactomannan (GM; weak
recommendation, moderate-quality evidence).
C2b. Do not use b-D-glucan (BG; strong recommendation, low-
quality evidence).
C2c. Do not use fungal polymerase chain reaction (PCR) testing in
blood (strong recommendation, moderate-quality evidence).
C3. In terms of imaging for the evaluation of prolonged
($ 96 hours) FN in IFD high-risk patients:
C3a. Perform computed tomography (CT) of the lungs (strong
recommendation, low-quality evidence).
C3b. Consider imaging of abdomen in patients without local-
izing signs or symptoms (weak recommendation, low-
quality evidence).
C3c. Consider not routinely performing CTof sinuses in patients
without localizing signs or symptoms (weak recommen-
dation, low-quality evidence).
Literature update and analysis. In the 2012 CPG, we included
recommendations related to surveillance and further investigation
of identified foci of infection such as lung nodules. In this CPG
update, we realized that these areas were outside of the scope of the
FN CPG and thus, those recommendations have been removed.
The 2017 FN CPG altered the recommendation related to GM
testing based on a recently conducted systematic review of fungal
biomarkers in pediatric cancer and HSCT.98 Eight studies assessed
GM as a diagnostic tool in children with symptoms potentially
suggestive of IFD, such as prolonged FN.99-106 Among these
studies, seven showed positive predictive values (PPV)# 75%, and
four studies showed PPV , 50%. Table 5 illustrates a clinical
vignette of GM testing in a population with a 10% risk of invasive
aspergillosis (IA) during FN and illustrates that using the pooled
sensitivity and specificity of 89% and 85% from the systematic
review, PPV would be 41% and negative predictive value (NPV)
Table 4. Synthesized Outcomes for Comparisons of Different Antibiotic Strategies
Comparison and Outcome Number of Studies
Number of
Episodes Effect 95% CI P
Aminoglycoside-containing combination
v monotherapy*†
Failure with modification included 9 672 RR 1.13 0.92 to 1.38 .23
Failure with modification excluded 4 289 RR 1.65 0.61 to 4.51 .33
Infection-related mortality 7 524 RR 1.99 0.58 to 6.85 .28
Overall mortality 3 269 RR 1.44 0.47 to 4.43 .52
Days of fever 6 546 MD -0.10 20.88 to 0.67 .80
Days of antibiotics 4 293 MD 0.71 21.20 to 2.61 .47
Adverse events 5 437 RR 0.93 0.54 to 1.60 .79
Antipseudomonal penicillin monotherapy v
fourth-generation cephalosporin monotherapy†
Failure with modification included 4 430 RR 0.95 0.75 to 1.21 .70
Infection-related mortality 4 509 RR 2.52 0.49 to 12.90 .27
Days of fever 3 296 MD -0.03 20.96 to 0.89 .94
Days of antibiotics 3 382 MD 0.81 0.15 to 1.47 .02
Inpatient v outpatient management†
Infection-related mortality 4 366 RR 1.60 0.37 to 6.88 .53
Overall mortality 3 339 RR 1.18 0.30 to 4.72 .81
Days of fever 3 228 MD -0.02 20.81 to 0.78 .97
Days of antibiotics 4 377 MD 0.17 20.47 to 0.82 .60
Days of hospitalization 3 340 MD 3.85 3.01 to 4.69 , .0001
Intravenous v oral empirical antibiotics†
Failure with modification included 4 526 RR 0.95 0.72 to 1.24 .70
Failure with modification excluded 5 613 RR 0.65 0.28 to 1.52 .32
Infection-related mortality 7 932 No events
Overall mortality 6 816 No events
Readmission 5 578 RR 0.50 0.23 to 1.08 .08
Intensive care unit 4 462 No events
Days of fever 6 758 RR 0.14 20.27 to 0.56 .50
Adverse events 4 459 RR 0.46 0.11 to 1.92 .29
Abbreviations: MD, mean difference; RR, risk ratio.
*Only monotherapy regimens considered appropriate for high-risk fever and neutropenia included in analysis.
†MD. 0 and RR. 1 favor monotherapy (v combination), fourth-generation cephalosporin (v antipseudomonal penicillin), outpatient (v inpatient) and oral (v intravenous)
therapy.
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would be 97%. Among 100 patients at high risk of IA evaluated,
testing would miss one patient with true infection and would
erroneously conclude IA in 14 patients without infection. Of the 23
children with a positive test, only nine would actually have IA; in
other words, most patients with a positive test in this clinical setting
will not have IA. The basis for the weak recommendation against
use of GM during FN was the poor PPV, and the limited usefulness
of high NPV because GM does not rule out non-Aspergillusmolds.
The recommendation related to BG testing remains un-
changed. In the systematic review of biomarkers for IFD,98 only
one study evaluated BG in an applicable setting,107 and it showed
PPV of 49% (95% CI, 32 to 66) and NPV of 96% (95% CI, 89 to
99), precluding clinical usefulness.
The updated CPG includes a new strong recommendation
against the use of fungal PCR in blood for evaluation of IFD during
prolonged FN based on eight studies99,108-114 that applied PCR in
a similar setting.109 Table 5 illustrates a clinical vignette of PCR
testing in a population with a 10% risk of IFD during FN and
illustrates that using the pooled sensitivity and specificity of 76%
and 58% from the systematic review, PPV would be 17% and NPV
would be 95%. Among 100 IFD high-risk patients evaluated,
testing would miss two patients with true infection and would
erroneously conclude IFD in 38 patients without infection. Of the
46 patients with a positive test, only eight would truly have IFD.
The basis for the strong recommendation against use of PCR is the
poor PPVand NPV, which were not sufficiently high to be clinically
useful. The Panel also noted the current lack of standardization for
PCR testing, which also makes clinical use challenging.
A limitation of the recommendations related to fungal bio-
markers is how we approached them as diagnostic tests and
evaluated their usefulness in detecting true disease. Randomized
trials comparing utilization with nonutilization of these bio-
markers to detect IFD would be a better approach to evaluation,
but such trials are unlikely to be feasible. In fact, our current
standard to recommend empirical antifungal therapy for IFD high-
risk patients with prolonged fever is based on the assumption that
prolonged fever is a good predictor of IFD when this factor has
never been evaluated as a diagnostic test. Comparative effectiveness
studies of fungal biomarker use may be the best way to bridge this
knowledge gap.
The data supporting recommendations related to imaging for
the evaluation of IFD during prolonged FN are shown in the Data
Supplement. A strong recommendation to perform lung CTs
remained unchanged in the updated CPG. Of the nine studies
evaluating lung CT115-123 for the evaluation of IFD, lungs were
usually the most frequent site of infection, and characteristic ra-
diographic signs were often observed. A new weak recommen-
dation for abdominal imaging even in the absence of localizing
signs or symptoms was made with this CPG update, based on the
systematic review (Data Supplement). Among the four studies
included,118,122-124 findings on imaging consistent with IFD were
observed in many patients without localizing signs or symptoms.
The Panel noted that the ideal imaging modality is not known, but
ultrasound is readily available, is not associated with radiation
exposure, and usually does not require sedation and thus, is likely
preferable over CT or magnetic resonance imaging for abdominal
assessment.
In the updated CPG, a revised weak recommendation
against routine sinus imaging was made in the absence of lo-
calizing signs or symptoms based on the systematic review
(Data Supplement). Among the five studies that described sinus
findings,118,122,123,125,126 sinus imaging was frequently abnor-
mal in prolonged FN, and abnormalities did not distinguish
between those with and without sinus IFD. It is a weak rec-
ommendation because studies directly addressing the useful-
ness of routine sinus CTs were limited.
Question
When should empirical antifungal therapy be initiated, what
antifungal agents are appropriate, and when is it appropriate to
discontinue empirical therapy?
Recommendations
C4. In IFD high-risk patients with prolonged ($ 96 hours) FN
unresponsive to broad-spectrum antibacterial agents, ini-
tiate caspofungin or liposomal amphotericin B (L-AmB) for
empirical antifungal therapy (strong recommendation,
high-quality evidence).
C5. In IFD low-risk patients with prolonged ($ 96 hours) FN,
consider withholding empirical antifungal therapy (weak
recommendation, low-quality evidence).
Literature update and analysis. Recommendations regard-
ing the choice of empirical antifungal agents in IFD high-risk
patients remain unchanged from the 2012 FN CPG, but they
are changed in IFD low-risk patients. Recommendations in IFD
high-risk patients were originally based on three RCTs127-129
demonstrating that caspofungin was as effective as L-AmB,127,128 and
that L-AmB was less nephrotoxic than amphotericin B deoxycholate.129
Either caspofungin or L-AmB was strongly recommended as empirical
Table 5. Clinical Implications of Fungal Biomarkers in the Diagnostic Setting
GM Fungal PCR
Pooled sensitivity = 0.89 Pooled sensitivity = 0.76
Pooled specificity = 0.85 Pooled specificity = 0.58
Positive predictive
value: 0.41
Positive predictive
value: 0.17
Negative predictive
value: 0.97
Negative predictive
value: 0.95
23 children will have a
positive test
46 children will have
a positive test
Nine will have IA
(true positives)
Eight will have IFD
(true positives)
14 will not have IA
(false positives)
38 will not have IFD
(false positives)
77 will have a negative
test
54 will have a negative
test
76 will not have IA (true
negatives)
52 will not have IFD
(true negatives)
One will have IA (missed
one of 10 with true
infection)
Two will have IFD (missed
two of 10 children with
true infection)
NOTE. The table assumes that serum GM and fungal PCR are performed in 100
consecutive IFD high-risk patients with prolonged FN. The pretest probability
(prevalence) of IFD in this high-risk population is estimated at 10% (10 patients will
truly have IFD). Pooled sensitivity and specificity were obtained from a systematic
review of biomarkers.78 Predictive values were directly calculated assuming 10%
prevalence of disease and using pooled sensitivity and specificity. Beta-D-glucan
was not included because synthesis in FN setting was not possible, given the
number of available studies.
Abbreviations: FN, fever and neutropenia; GM, galactomannan; IA, invasive
aspergillosis; IFD, invasive fungal disease; PCR, polymerase chain reaction.
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antifungal therapy. One recent study prospectively compared admin-
istration of empirical antifungal therapy versus withholding empirical
antifungal therapy in neutropenic children with persistent fever who
were IFD low-risk. No benefit relative to fever resolution or IFD was
detected from empirical antifungal therapy.127
No RCTs addressed empirical antifungal therapy cessation or
a pre-emptive antifungal therapy approach and thus, original
recommendations were unchanged. Both of these areas remain
important knowledge gaps in pediatric FN.
DISCUSSION
We updated the 2012 FN CPG for children with cancer and
HSCT recipients. Although most recommendations remained
unchanged, some key differences emerged. Changes included the
listing of a fourth-generation cephalosporin for empirical therapy,
refinement of IFD risk stratification, changes in recommended
biomarkers and radiologic investigations for the evaluation of IFD,
and a weak recommendation to withhold empirical antifungal
therapy in IFD low-risk patients.
Implementation is an important issue, and national and
international guidance will be important to effect change.
Adaptation will be required at the institutional level to delineate
specific rather than generic antibiotic choices and to decide
whether to implement or not implement weak recommenda-
tions. Decision making for weak recommendations could also be
made at the specific provider or patient level. Cost-effectiveness
studies may be relevant when deciding whether to implement
weak recommendations.
Changes to the updated FN CPG recommendations will likely
influence the care of children with cancer and pediatric patients
undergoing HSCT. Future work should focus on closing research
gaps and identifying ways to facilitate implementation.
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